Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know

In the latest close session, Novo Nordisk (NVO) was down 2.14% at $40.29. This move lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.57%, and the technology-dominated Nasdaq saw an increase of 0.04%. Shares of the drugmaker witnessed a gain of 12.03% over the previous month, beating the performance of the Medical sector with its loss of 0.72%, and underperforming the S&P 500's gain of 12.24%.Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. The company's upcoming EPS is projected at $0.87, signifying a 5.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 1.08% from the year-ago period. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.34 per share and a revenue of $45.44 billion, representing changes of -15.66% and -2.87%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.6% decrease. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now. Looking at its valuation, Novo Nordisk is holding a Forward P/E ratio of 12.34. For comparison, its industry has an average Forward P/E of 13.88, which means Novo Nordisk is trading at a discount to the group. Also, we should mention that NVO has a PEG ratio of 9.8. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.23. The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 169, positioning it in the bottom 31% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. 7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks